Johnson & Johnson (NYSE:JNJ) Stock Price Target Raised at JPMorgan Chase & Co.

Johnson & Johnson (NYSE:JNJ – Free Report) had its target price increased by JPMorgan Chase & Co. from $285.00 to $300.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other research analysts also recently issued reports on JNJ. Royal Bank Of Canada reduced their price target on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 14th. Citigroup boosted their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Finally, Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $276.54.

Check Out Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Stock Up 1.3%

Shares of JNJ opened at $270.54 on Friday. The company has a market capitalization of $651.27 billion, a P/E ratio of 40.99, a PEG ratio of 2.79 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a one year low of $199.90 and a one year high of $290.25. The business’s 50 day simple moving average is $267.53 and its 200-day simple moving average is $250.98.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same period last year, the firm posted $2.80 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is presently 81.21%.

Insider Transactions at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 13,072 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in shares of Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Fisher Asset Management LLC lifted its position in shares of Johnson & Johnson by 11.5% in the third quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock worth $3,927,981,000 after purchasing an additional 1,530,070 shares in the last quarter. Amundi boosted its holdings in Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares during the last quarter. Finally, Jupiter Topco LLC acquired a new position in Johnson & Johnson during the second quarter worth $1,967,399,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Top Johnson & Johnson Stories

These are some of the JNJ stories that stood out recently:

  • Positive Sentiment: Phase 4 results for TREMFYA in axial psoriatic arthritis met key endpoints, with significant symptom improvement and more than twice the placebo reduction in MRI-assessed inflammation. The data could strengthen the drug’s commercial prospects. Article
  • Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and increased damages, reinforcing ongoing litigation exposure for J&J. Article

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

See Also

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.